Related Experiment Video

Updated: Aug 17, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Gene therapy for arthritis

C H Evans1, P D Robbins

  • 1Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, C-313 Presbyterian University Hospital, 200 Lothsop Street, Pittsburgh, PA 15213, USA.

Expert Opinion on Investigational Drugs
|July 1, 1997
PubMed

Insights

Gene therapy shows promise for arthritis, with preclinical data demonstrating anti-arthritic effects. Clinical trials are underway for rheumatoid arthritis, and potential applications extend to osteoarthritis and tissue repair.

Area of Science:

  • Orthopedics and Sports Medicine
  • Molecular Biology
  • Rheumatology

Background:

  • Recent advancements in gene therapy for arthritis have shown significant progress.
  • Challenges remain in vector development and achieving sustained gene expression.

Purpose of the Study:

  • To review the latest developments in arthritis gene therapy.
  • To highlight emerging preclinical and clinical findings.

Main Methods:

  • Transfer of cytokine antagonist genes to joints.
  • Investigating cytotoxic gene transfer for synovectomy.
  • Exploring oligonucleotide transfer to antagonize transcription factors.

Main Results:

  • Preclinical data in animal models demonstrate a significant anti-arthritic effect of cytokine antagonist gene transfer.
  • Two human clinical trials for rheumatoid arthritis have commenced.
  • Preliminary data suggest potential benefits for osteoarthritis and tissue regeneration.

Conclusions:

  • Gene therapy holds considerable promise for treating various forms of arthritis.
  • Ongoing research is exploring diverse gene-based strategies for joint diseases and repair.

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...